BRIEF-Exopharm Says Ian Dixon's Employment As CEO Expected To End In Early 2024

Reuters2023-11-28

Nov 28 (Reuters) - Exopharm Ltd :

* IAN DIXON EMPLOYMENT AS CEO IS EXPECTED TO END IN EARLY CY 24.

* IS MINIMISING NON- ESSENTIAL COSTS

* WORKING TO BRING POTENTIAL TRANSACTION TO SHAREHOLDERS AND HAVE COMPANY'S SHARES RECOMMENCE TRADING

* DETERMINED THAT A FULL-TIME CEO ROLE WILL NOT BE REQUIRED GOING FORWARD

* SEEKING A TRANSACTION THAT COULD RESULT IN A MATERIAL CHANGE IN COMPANY'S ACTIVITIES

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2386500631?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-11-28 08:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2386500631","market":null,"top_or_hot":-1,"title":"BRIEF-Exopharm Says Ian Dixon's Employment As CEO Expected To End In Early 2024","media":"Reuters","content":"<html><body><p>Nov 28 (Reuters) - <a href=\"https://laohu8.com/S/EXOPF\">Exopharm Ltd</a>   :</p><p>   * IAN DIXON EMPLOYMENT AS CEO IS EXPECTED TO END IN EARLY CY 24.</p><p>   * IS MINIMISING NON- ESSENTIAL COSTS</p><p>   * WORKING TO BRING POTENTIAL TRANSACTION TO SHAREHOLDERS AND HAVE COMPANY'S SHARES RECOMMENCE TRADING</p><p>   * DETERMINED THAT A FULL-TIME CEO ROLE WILL NOT BE REQUIRED GOING FORWARD</p><p>   * SEEKING A TRANSACTION THAT COULD RESULT IN A MATERIAL CHANGE IN COMPANY'S ACTIVITIES</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Exopharm Says Ian Dixon's Employment As CEO Expected To End In Early 2024</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Exopharm Says Ian Dixon's Employment As CEO Expected To End In Early 2024\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-11-28 08:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nov 28 (Reuters) - Exopharm Ltd   :   * IAN DIXON EMPLOYMENT AS CEO IS EXPECTED TO END IN EARLY CY 24.   * IS MINIMISING NON- ESSENTIAL COSTS   * WORKING TO BRING POTENTIAL TRANSACTION TO SHAREHOLDERS...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EX1.AU","symbol_name":"EXOPHARM LTD","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2386500631","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2386500631","pubTimestamp":1701133199,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Nov 28  - Exopharm Ltd   :   * IAN DIXON EMPLOYMENT AS CEO IS EXPECTED TO END IN EARLY CY 24.   * IS MINIMISING NON- ESSENTIAL COSTS   * WORKING TO BRING POTENTIAL TRANSACTION TO SHAREHOLDERS AND HAVE COMPANY'S SHARES RECOMMENCE TRADING   * DETERMINED THAT A FULL-TIME CEO ROLE WILL NOT BE REQUIRED GOING FORWARD   * SEEKING A TRANSACTION THAT COULD RESULT IN A MATERIAL CHANGE IN COMPANY'S ACTIVITIESSource text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EX1.AU":"EXOPHARM LTD","BK7067":"生物科技"},"translate_title":"简介——Exopharm表示，伊恩·迪克森的首席执行官任期预计将于2024年初结束","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EX1.AU":0.9},"content_text":"Nov 28 (Reuters) - Exopharm Ltd   :   * IAN DIXON EMPLOYMENT AS CEO IS EXPECTED TO END IN EARLY CY 24.   * IS MINIMISING NON- ESSENTIAL COSTS   * WORKING TO BRING POTENTIAL TRANSACTION TO SHAREHOLDERS AND HAVE COMPANY'S SHARES RECOMMENCE TRADING   * DETERMINED THAT A FULL-TIME CEO ROLE WILL NOT BE REQUIRED GOING FORWARD   * SEEKING A TRANSACTION THAT COULD RESULT IN A MATERIAL CHANGE IN COMPANY'S ACTIVITIESSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2386500631"}